ICON Named by Forbes as One of the Best Employers in America
May 11 2017 - 6:00AM
Business Wire
Forbes ranking of top employers drawn from a
survey of 30,000 US employees in 25 industry sectors
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has been included in Forbes magazine’s America’s Best Employers
list for 2017.
Now in its third year, the Forbes list features the top 500
large employers in the US with more than 5,000 employees and the
top 300 midsize companies with 1,000 – 5,000 employees. ICON was
the highest ranked CRO in the best midsize employers listing.
The Forbes list is determined following an independent, online
survey of 30,000 employees representing companies from 25 industry
sectors. In conjunction with consumer research provider, Statista,
employees were consulted anonymously in September 2016 through
several online panels to allow them to share their opinions about
their employers openly and without any influence from their
employer. Respondents were asked to rate their willingness to
recommend their own companies on a scale of 0 – 10 and were also
asked to name good and bad employers in industry sectors other than
their own.
“We are proud to be named by Forbes as one of the best employers
in America and we are pleased that our employees are recommending
ICON as an excellent place to work,” commented Dr. Steve Cutler,
Chief Executive Officer, ICON. “We have great people who are
committed to helping our clients to accelerate the development of
drugs and devices that are saving lives and improving the quality
of life of patients right across the globe. We will continue to
work hard to ensure that we provide a work environment that
engages, rewards and develops our employees so that they can build
successful careers at ICON.”
About ICON
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 87 locations in 38 countries and has approximately
12,300 employees. Further information is available at
www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170511005097/en/
ICON Media ContactCamille FrederixWeber ShandwickTel: +44
(0)207 067 0272Email: cfrederix@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2023 to Apr 2024